Sign in
4

Changes in Ownership

CORCEPT THERAPEUTICS INC Filed Acc 0001193125-25-307282

Chief Development Officer sold 20,000 shares at an average $80.08 ($1,601,526)

  • Chief Development Officer acquired 20,000 shares (option exercise)
  • Chief Development Officer acquired 448 shares (grant or award)
  • Chief Development Officer gave 787 shares (gift)
  • Chief Development Officer acquired 787 shares (other)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Guyer William Chief Development Officer 2025-12-01 Grant or award 10b5-1 +224 $79.78 $17,871 224 D: show line 1 in the form
Guyer William Chief Development Officer 2025-12-01 Grant or award 10b5-1 +224 448 D: show line 2 in the form
Guyer William Chief Development Officer 2025-12-02 Gift 10b5-1 −787 0 I: show line 3 in the form
Guyer William Chief Development Officer 2025-12-02 Other acquisition 10b5-1 +787 1,235 D: show line 4 in the form
Guyer William Chief Development Officer 2025-12-02 Option exercise 10b5-1 +20,000 $21.65 $433,000 21,235 D: show line 5 in the form
Guyer William Chief Development Officer 2025-12-02 Sale 10b5-1 −19,360 $80.05 $1,549,766 1,875 D: show line 6 in the form
Guyer William Chief Development Officer 2025-12-02 Sale 10b5-1 −640 $80.88 $51,760 1,235 D: show line 7 in the form
Open-market sales · 20,000 sh · avg $80.08 · $1,601,526

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Guyer William Chief Development Officer 2025-12-02 Option exercise · Stock option (right to buy) 10b5-1 −20,000 270,000 D: show line 8 in the form
Loading xslF345X05/ownership.xml…